Icon plans network of vendors to speed patient recruitment

By Nick Taylor

- Last updated on GMT

Icon plans network of vendors to speed patient recruitment
Icon wants to create a “jigsaw” of patient recruitment vendors to speed enrolment and differentiate it from other CROs.

By partnering with a network of patient recruitment vendors Icon hopes to gain access to assets that can help clients overcome the long-standing clinical trial bottleneck of enrolment. If successful, the project should help Icon stand out in the highly competitive clinical research services sector.

Steve Cutler, group president, clinical research services at Icon, told Outsourcing-Pharma: “We’re looking at patient recruitment as a key strategic differentiator​.” Icon is yet to find one vendor that can give it all the capabilities it wants so is building a network of partners with different strengths.

One reason for the lack of a single vendor with expertise in all areas of patient recruitment is the variety of challenges posed by different therapeutic fields. A “customised approach​” is needed for each disease area, Cutler said, and Icon is currently assessing where potential partners are weak.

The need for occasional expertise in esoteric therapeutic areas means Icon consults with third-party experts on other aspects of clinical trials. In the big therapeutic fields Icon is content with its in-house knowledge though.

I think the big CROs have as much knowledge as the big pharma companies​”, Cutler said. In the long-term Cutler thinks Icon could build its drug development knowhow to offer consulting services like those now provided by McKinsey.

Looking at late phase

Over the past year Icon has added to its in-house expertise with the acquisitions of Oxford Outcomes and PriceSpective. The takeovers gave Icon market access and outcomes capabilities and more deals are possible.

Icon is content with its late phase capabilities, Cutler said, but may expand the unit geographically. A takeover in China is possible as Icon looks to meet client demand in the country and benefit from a shift in attitudes to late phase outsourcing.

I think clients are becoming more comfortable outsourcing Phase IV trials​”, Cutler said. As clients become open to outsourcing activities previously handled in-house Cutler wants Icon to be “more assertive” and push penetration up towards 60 per cent.

Related news

Show more

Related products

show more

Using Define-XML to build more efficient studies

Using Define-XML to build more efficient studies

Content provided by Formedix | 14-Nov-2023 | White Paper

It is commonly thought that Define-XML is simply a dataset descriptor: a way to document what datasets look like, including the names and labels of datasets...

Overcoming rapid growth challenges with process liquid preparation

Overcoming rapid growth challenges with process liquid preparation

Content provided by Thermo Fisher Scientific - Process Liquid Preparation Services | 01-Nov-2023 | Case Study

A growing contract development manufacturing organization (CDMO) was challenged with the need to quickly expand their process liquid and buffer preparation...

Why should you use clinical trial technology?

Why should you use clinical trial technology?

Content provided by Formedix | 01-Nov-2023 | White Paper

New, innovative clinical trial technology is helping to revolutionize the research landscape. COVID-19 demonstrated that clinical trials can be run much...

Related suppliers

Follow us

Products

View more

Webinars